JACC-Heart Failure

Article	Citations
Call for Fine Remote Monitoring of Prognostic Signs and Symptoms in Heart Failure	204
Everything I Wanted	163
Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure	152
Guideline-Recommended Therapy Following Hospitalization for Heart Failure	137
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status	111
Opportunities for Change in Home Health Care in Heart Failure	93
Topping Off the Pill Box	88
Blood Volume Analysis-Guided Heart Failure Management	84
Immune Checkpoint Inhibitors Myocarditis	80
The EVOLVeD Role of Cholesterol-Lowering Therapies in Cardiac Allograft Vasculopathy	72
Simplifying Treatment of Congestion	70
Combining Loop and Thiazide Diuretics Across the Left Ventricular Ejection Fraction Spectrum	66
Wearable Remote Patient Monitoring Devices	64
Impact of Inpatient Percutaneous Coronary Intervention Volume on 30-Day Readmissions After Acute Myocardial Infarction-Cardiogenic Shock	60
Heart Transplant and Pregnancy	56
Donor Selection for Heart Transplantation in 2025	56
Atrial Fibrillation and Heart Failure	55
Desire for Prognostic Information Among Persons With Advanced Heart Failure	55
Management of Patients With Impella 5.5 Left Ventricular Assist Devices on a Cardiovascular Stepdown Unit	52
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF	51
Advanced Cardiovascular Imaging in Clinical Heart Failure	50
Accepting the Pulmonary Artery Catheter for Cardiogenic Shock	48
How to Skydive Without a Parachute	47
Officers Page	45
Table of Contents	44

Metabolic Risk Score in Heart Failure	44
Full Issue PDF	44
The Advanced Heart Failure and Transplant Cardiology Fellowships Match	42
Shifting the Paradigm of Risk From Resting to Exercise-Induced Blood Pressure Changes in HFpEF	41
Expenditure on Heart Failure in the United States	40
Pharmacologic Heart Rate Modulation in Heart Failure With Preserved Ejection Fraction	40
Insights From the History and Physical Examination in HFpEF or HFrEF	39
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies	39
Clinical Predictors of Referral for and Yield of Genetic Testing in Peripartum Cardiomyopathy	39
Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk	38
Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation	37
Cardiac Resynchronization Therapy in Ischemic Versus Nonischemic Cardiomyopathy	37
The Evaluation of Digital Technologies for Heart Failure Management	37
Depression and Suicide in Patients Newly Diagnosed With Heart Failure	35
A Step Forward Toward a New Treatment Paradigm in the Cardiorenal Continuum	35
A Multiple Hit Model for Genetic Susceptibility to Cardiomyopathy	35
Genetic Testing for Myocarditis	35
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans	34
Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection Fraction	34
The Association of Echocardiographically Measured Donor Left Ventricular Mass and 1-Year Outcomes After Heart Transplantation	34
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy	33
Heart Failure Risk Among African-American Women With an ICAM1 Missense Variant	32
Controversies and Conundrums in Cardiac Cachexia	32
Vericiguat and Total Heart Failure Hospitalizations	32
Predictors of Incident Heart Failure Diagnosis Setting	31
The Pathophysiological and Therapeutic Implications of Cardiac Light-Chain Amyloidosis Compared With Transthyretin Amyloidosis	31
Incidence and Prediction of Anoxic Brain Injury in Concomitant Cardiac Arrest and Cardiogenic Shock	30
Dapagliflozin in Heart Failure, Type 2 Diabetes, and Neuropathy	30
Impact of Digital Health Technology on Quality of Life in Patients With Heart Failure	30
Cardiomyocyte DNA Damage Predicts Functional Recovery in Heart Failure Patients	30
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status	30
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction	29
Middle-Aged Children With Heart Failure	29
Use of Digital Devices in Patients With Heart Failure	29
Sex Differences in Heart Failure With Improved Ejection Fraction	28
Is Reducing Heart Failure Hospitalization Associated With Reducing Mortality in Heart Failure Trials?	27
Is an ECG Even Necessary?	27
Effect of Training on Vascular Function and Repair in Heart Failure With Preserved Ejection Fraction	27
Beta-Blockers in HFpEF	27
Omega-3	27
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure	27
How to Measure DELIVERed Benefits of Dapagliflozin in the Management of HFmrEF/HFpEF?	26
Reply	26
Sex Differences in Prognosis of Heart Failure Due to Chronic Chagas Cardiomyopathy	25
Bio-Profiling of Transthyretin Amyloid Cardiomyopathy	25
Missing the True Target in Advanced Heart Failure	24
Proteomics as a Path to More Refined Heart Failure Therapeutics	24
Mitral Regurgitation in Acute Decompensated Heart Failure	24
Reply	24
Pulmonary Artery Catheter in Cardiogenic Shock	23

Poor Self-Rated Knowledge About Self-Care Behavior in Patients With Advanced Heart Failure	23
2 Heart Failure Specialists Amid 2 Earthquakes 2 Decades Apart	22
Risks of Depression and Suicide After Diagnosis With Heart Failure	22
Reply	21
Reply	21
Step by Step	21
Beyond the Status Quo	21
Spirituality and Outcome in Chronic Diseases	21
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure	21
Information for Authors	20
Residual Heart Failure on Mechanically Assisted Circulation	20
Heart Failure in Women	20
Reply	20
SGLT2 Inhibitors and Blood Pressure in Heart Failure	20
Unexpected Low Natriuretic Peptide Levels	20
Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy	19
Remote Dielectric Sensing Before and After Discharge in Patients With ADHF	19
The HeartMate 3 Risk Score	19
Instructions for Authors	19
Long-Term Effects of Sotatercept on Right Ventricular Function	19
GDMT Initiation	19
Obesity Status and Physical Rehabilitation in Older Patients Hospitalized With Acute HF	18
Context for Deciding Therapy in Mitral Regurgitation	18
Cost and Value in Contemporary Heart Failure Clinical Guidance Documents	18
Pre–Heart Failure	18
Full issue PDF	18
Concerning Trends of Rising Heart Failure Mortality Rates	18
The Vexing Problem of HFpEF Therapeutics	18
Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization	18
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction	17
Association of Histologic Findings With Long-Term Outcomes in Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients Undergoing Surgical Myectomy	17
Long-Term Response of Obstructive Hypertrophic Cardiomyopathy Patients to Mavacamten Based on Sex	17
m-Health Based Cardiac Rehabilitation Program for Management of Older Patients With HFpEF	17
Safety and Performance of the Aortix Device in Acute Decompensated Heart Failure and Cardiorenal Syndrome	17
Empower the Future… Even Oprah Had a Mentor!	16
Will Knowing More Translate Into More Organs?	16
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function	16
Race-Based Analyses in Heart Failure Clinical Trials	16
Influence of Obesity on Invasive Hemodynamics and Prognosis in Patients With Heart Failure	16
From Clinical Trials to Communities	16
Developing a System for Best Performance for Cardiac Transplantation	16
Mineralocorticoid Receptor Antagonists and SGLT2 Inhibitor Therapy	16
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction	15
Modifiable Mechanical Ventilation Targets Are Associated With Improved Survival in Ventilated VA-ECLS Patients	15
Surviving the Pandemic With Heart Failure	15
Reply	15
Prognostic Implications of N-Terminal Pro–B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved	15
Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure	15
Curing Ourselves of Toxic Positivity for Hospital-at-Home	14
Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction	14
Doing Our Part to Get With the Heart Failure Guidelines	14
Eating to Prevent Both Heart and Planetary Failure	14
LVAD Weaning	14
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States	14
Waiting for Godot?	14
Exercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction	14
Redefining Boundaries in Heart Failure Care	13
Exciting Developments at JACC: Heart Failure	13
Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults	13
Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure	13
Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality	13
Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure	13
Left Ventricular Assist Devices Versus Heart Transplantation for End Stage Heart Failure is a Misleading Equivalency	13
Standardizing Histopathological Evaluation of Resected Myocardium in Obstructive Hypertrophic Cardiomyopathy	13
Cardiopulmonary Resuscitation in Patients With Left Ventricular Assist Devices	13
Editorial Board	13
Correction	12
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease	12
Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry	12
Pregnancy as a Sentinel Event	12
Outpatient Management of Heart Failure During the COVID-19 Pandemic After Adoption of a Telehealth Model	12
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score	12
Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation	12
Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction	12
Reply	12
Successful Decongestion as a Clinical Target, Performance Indicator, and as a Study Endpoint in Hospitalized Heart Failure Patients	12
Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death	12
Correction	12
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction	11
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	11

Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF	11
Fibrosis Biomarkers Predict Cardiac Reverse Remodeling	11
Acute Myocarditis Associated With Desmosomal Gene Variants	11
The End of Endomyocardial Biopsy?	11
Renal Compression in Heart Failure	10
Expenditure on Heart Failure in the United States	10
Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction	10
1 Year HIIT and Omega-3 Fatty Acids to Improve Cardiometabolic Risk in Stage-A Heart Failure	10
Differentiation Between Worsening Heart Failure and Decompensated Heart Failure	10
Prevalence of Pathogenic Variants in Cardiomyopathy-Associated Genes in Acute Myocarditis	10
Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction	10
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia	10
Utility and Validity of the HFA-PEFF and H2FPEF Scores in Patients With Symptomatic Atrial Fibrillation	10
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF	10
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome	10
Heart Failure Risk Linked to Adverse Pregnancy Outcomes	9
Full Issue PDF	9
Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan	9
Personalizing Risk Assessment for Sudden Cardiac Death in Heart Failure	9
Palliative Care Utilization in Patients With Heart Failure With Preserved Ejection Fraction	9
Editorial Board	9
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	9
Racial and Genetic Differences	9
What Drives Transplant Outcomes Following Donation After Circulatory Death	9
Cardiopulmonary Exercise Testing With Simultaneous Echocardiography	9
Apparent Treatment-Resistant Hypertension	8
The Pressure for Progress in Heart Failure	8
Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment	8
Impact of SGLT2 Inhibitors on Serum Sodium in Heart Failure With Reduced Ejection Fraction	8
Reply	8
Trajectories of Kidney Function in Heart Failure Over a 15-Year Follow-Up	8
Are High-Volume Cardiologists Ready for EHR Best Practice Alerts?	8
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events	8
Balancing Expectations	8
Thank You for the Privilege	8
If Heart Failure Medications Provide So Much Benefit, Why Do So Few Patients Receive Them?	8
The Urgent Need for More Cardiac Rehabilitation in the Aim to “Preserve” Patients With Heart Failure	8
Elevated Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Acute Myocarditis	8
Pulse Pressure Augmentation During Exercise	8
When Tissue Matters	8
Pregnancy in Patients With Advanced Heart Failure	8
Can We Manage Presymptomatic TTR V142I Related Risk?	8
Survival of the Fittest	8
Where There’s Smoke, There’s Fire	8
Long-Term Quality of Life Response Observed in the Baroreflex Activation Therapy for Heart Failure Trial	8
Association of Multiple Nonhypertrophic Cardiomyopathy–Related Genetic Variants and Outcomes in Patients With Hypertrophic Cardiomyopathy	8
Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure	7
Maternal Bereavement and Heart Failure Risk of the Offspring	7
Influence of Impaired Conduction on Exercise Hemodynamics in Patients With Preserved Ejection Fraction	7
Plasma Ferritin Levels, Incident Heart Failure, and Cardiac Structure and Function	7
Reply	7
Left Atrial-to-Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	7
Correction	7
Editorial Board	7
Preeclampsia in Heart Transplant Recipients	7
Full issue PDF	7
NT-proBNP	7
Table of Contents	7
Prevalence of Subclinical Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction	7
Racial Differences in Natriuresis	7
Need to Define Severe Heart Failure	7
Treatment of Heart Failure Related Cardiogenic Shock	7
Challenges Addressing Prognosis in Advanced Heart Failure	7
Change Is the Only Constant in Heart Failure	7
Compensation Models in Heart Failure	7
Complications and Mortality Following CRT-D Versus ICD Implants in Older Medicare Beneficiaries With Heart Failure	7
Reply	7
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy	7
The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis	7
Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure	7
Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction	7
Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF	7
Fine-Tuning Risk Stratification in Heart Failure	6
Reply	6
Clinical Trial Inclusion and Impact on Early Adoption of Medical Innovation in Diverse Populations	6
Prevalence and Implications of Heart Failure Stages A-D Among Patients With Chronic Kidney Disease	6
The Heart of the Matter	6
Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical Sensors	6
Looking Under the Hood of the “Good” Cholesterol	6
The Path Toward a More Equitable Transplant System	6
Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials	6
HFrEF Progress for Women Remains Stagnant	6
Relationship of Dapagliflozin With Serum Sodium	6
Inhibiting Both Neprilysin and Phosphodiesterase Type 9	6
Reversal of Frailty	6
Insights and Queries on Donor ECG’s Role in Heart Transplants	6
Full issue PDF	6
Empagliflozin-Induced Changes in Epicardial Fat	6
Heart Failure in Women	6
Hospital at Home as a Novel Care Strategy for Worsening Heart Failure	6
Epidemiology of Heart Failure and the Discovery of the Cardioprotective Effects of SGLT2 Inhibitors	5
Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure	5
Device Interventions for Heart Failure	5
Endothelin Receptor Antagonists and Risk of Heart Failure in CKD	5
Reply	5